不安障害の治療の世界市場

不安障害の治療の世界市場は2030年までに121億米ドルに達する見込み

2023年に102億米ドルと推定される不安障害の治療の世界市場は、2023年から2030年にかけてCAGR 2.4%で成長し、2030年には121億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗うつ薬は、CAGR 3.0%を記録し、分析期間終了時には49億米ドルに達すると予測されます。抗不安薬セグメントの成長率は、分析期間中CAGR 2.6%と推定されます。

米国市場は28億米ドル、中国はCAGR 4.3％で成長すると予測

米国の不安障害の治療市場は、2023年に28億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGRを4.3%として、2030年までに24億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3%と2.2%と予測されています。欧州では、ドイツがCAGR 1.7%で成長すると予測されています。

不安障害の治療-主要動向と促進要因

不安障害の治療には、全般性不安障害（GAD）、パニック障害、社交不安障害、特定の恐怖症など、さまざまな不安障害の症状を緩和するためにデザインされた、さまざまな治療アプローチと薬剤が含まれます。これらの治療は、過剰な恐怖、心配、および日常機能に大きな影響を及ぼす関連行動の変化を軽減することを目的としています。心理療法、特に認知行動療法（CBT）は、不安障害の最前線の治療法と考えられています。CBTは、患者が否定的な思考パターンや行動を特定し修正するのを助け、不安を管理する対処戦略を教えます。その他の治療アプローチとしては、患者をコントロールされた方法で徐々に恐怖の状況にさらす暴露療法や、患者が行動を変えることを約束しながら不安を受け入れるよう促す受容コミットメント療法（ACT）などがあります。

薬物療法は不安障害の治療のもう1つの要であり、しばしば心理療法と併用されます。選択的セロトニン再取り込み阻害薬（SSRI）とセロトニン・ノルエピネフリン再取り込み阻害薬（SNRI）は、その有効性と比較的良好な副作用プロファイルにより、第一選択薬として一般的に処方されます。ベンゾジアゼピン系薬剤は、短期的な緩和には有効であるが、依存や離脱の問題のリスクがあるため、一般的には慎重に処方されます。さらに、不安の身体症状を管理するために一般的に使用されるβ遮断薬や、治療抵抗性の症例に対する非定型抗精神病薬など、他のクラスの薬剤も利用されます。最近の薬物療法の動向は、患者により良い結果をもたらすために、副作用が少なく、グルタミン酸系やエンドカンナビノイド系を標的とするような新しい作用機序を持つ薬剤の開発に焦点を当てています。

不安障害の治療市場の成長は、いくつかの要因によってもたらされます。第一に、世界的に不安障害の有病率が上昇していることが重要な促進要因であり、認知度と診断の向上が効果的な治療に対する需要の増加に寄与しています。第二に、デジタルヘルスにおける技術的進歩により、遠隔治療やモバイルヘルスアプリケーションを通じてメンタルヘルスケアへのアクセスが拡大し、特に遠隔地での治療がより身近なものとなっています。第三に、メンタルヘルスにまつわる偏見が徐々に薄れ、より多くの人が治療を受けるようになっています。さらに、薬物療法の継続的な研究開発により、有効性と安全性が改善された革新的な治療法が生まれています。さらに、プライマリ・ケア設定へのメンタルヘルス・サービスの統合は、不安障害の特定と管理を改善しています。最後に、政府の好意的な政策とヘルスケア支出の増加は、メンタルヘルス治療の開拓とアクセシビリティを支援し、市場の成長をさらに促進しています。これらの要因が総合的に、不安障害の治療市場のダイナミックで発展的な性質を浮き彫りにし、世界のメンタルヘルス成果の改善における重要な役割を強調しています。

調査対象企業の例（全63件）

• Abbott Laboratories, Inc.
• Allergan PLC
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Noven Pharmaceuticals, Inc.
• Pfizer, Inc.
• Shionogi & Co., Ltd.
• Sumitomo Dainippon Pharma Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Anxiety Disorder Treatment Market to Reach US$12.1 Billion by 2030

The global market for Anxiety Disorder Treatment estimated at US$10.2 Billion in the year 2023, is expected to reach US$12.1 Billion by 2030, growing at a CAGR of 2.4% over the analysis period 2023-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$4.9 Billion by the end of the analysis period. Growth in the Anxiolytics segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.8 Billion While China is Forecast to Grow at 4.3% CAGR

The Anxiety Disorder Treatment market in the U.S. is estimated at US$2.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 4.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Anxiety Disorder Treatment - Key Trends and Drivers

Anxiety disorder treatment encompasses a range of therapeutic approaches and medications designed to alleviate the symptoms of various anxiety disorders, including generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and specific phobias. These treatments aim to reduce excessive fear, worry, and associated behavioral changes that significantly impact daily functioning. Psychotherapy, particularly cognitive-behavioral therapy (CBT), is considered a frontline treatment for anxiety disorders. CBT helps patients identify and modify negative thought patterns and behaviors, teaching coping strategies to manage anxiety. Other therapeutic approaches include exposure therapy, which gradually exposes patients to feared situations in a controlled manner, and acceptance and commitment therapy (ACT), which encourages patients to accept their anxiety while committing to behavior changes.

Medications are another cornerstone of anxiety disorder treatment, often used in conjunction with psychotherapy. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly prescribed first-line medications due to their efficacy and relatively favorable side effect profiles. Benzodiazepines, while effective for short-term relief, are generally prescribed with caution due to the risk of dependency and withdrawal issues. Additionally, other classes of medications such as beta-blockers, which are typically used to manage physical symptoms of anxiety, and atypical antipsychotics for treatment-resistant cases, are also utilized. Recent advancements in pharmacotherapy are focusing on developing medications with fewer side effects and novel mechanisms of action, such as targeting the glutamate system or the endocannabinoid system, to provide better outcomes for patients.

The growth in the anxiety disorder treatment market is driven by several factors. Firstly, the rising prevalence of anxiety disorders globally is a significant driver, with increasing awareness and diagnosis contributing to higher demand for effective treatments. Secondly, technological advancements in digital health are expanding access to mental health care through teletherapy and mobile health applications, making treatments more accessible, especially in remote areas. Thirdly, the stigma around mental health is gradually diminishing, encouraging more individuals to seek treatment. Moreover, continuous research and development in pharmacotherapy are leading to innovative treatment options with improved efficacy and safety profiles. Additionally, the integration of mental health services into primary care settings is improving the identification and management of anxiety disorders. Lastly, favorable government policies and increasing healthcare expenditure are supporting the development and accessibility of mental health treatments, further propelling market growth. These factors collectively highlight the dynamic and evolving nature of the anxiety disorder treatment market, emphasizing its critical role in improving mental health outcomes globally.

Select Competitors (Total 63 Featured) -

• Abbott Laboratories, Inc.
• Allergan PLC
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Noven Pharmaceuticals, Inc.
• Pfizer, Inc.
• Shionogi & Co., Ltd.
• Sumitomo Dainippon Pharma Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Anxiety Disorder Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Anxiety Disorders Throws the Spotlight on Need for Effective Treatments
  • Adoption of Digital Therapeutics in Anxiety Management Spurs Market Expansion
  • Integration of Mental Health Services into Primary Care Strengthens Business Case for Comprehensive Care Models
  • Continuous Research and Development in Pharmacotherapy Generates New Treatment Options
  • Innovations in Psychotherapy Techniques Improves Patient Outcomes
  • Rising Utilization of Mobile Health Applications Drives Demand for Accessible Treatment Options
  • Development of Medications with Novel Mechanisms of Action Expands Therapeutic Landscape
  • Growing Popularity of Acceptance and Commitment Therapy (ACT) Generates Interest in Alternative Therapies
  • Advances in Understanding of Neurobiological Mechanisms Propel Growth in Personalized Medicine
  • Growing Investment in Mental Health Infrastructure Expands Addressable Market Opportunity
  • Rising Awareness of Comorbid Conditions Drives Comprehensive Treatment Strategies
  • Expansion of Insurance Coverage for Mental Health Services Strengthens Business Case for Providers
  • Growth in Corporate Mental Health Programs Generates Demand for Anxiety Disorder Treatments
  • Advances in Genetic Research Propel Growth in Targeted Anxiety Therapies
  • Increasing Consumer Preference for Non-Pharmacological Treatments Drives Adoption of Alternative Therapies
  • Challenges in Medication Side Effects Create Opportunities for New Drug Development
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Anxiety Disorder Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Anxiety Disorder Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Anxiolytics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Anxiolytics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Anxiolytics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Noradrenergic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Noradrenergic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Noradrenergic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Atypical Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Atypical Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Atypical Antipsychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• JAPAN
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• CHINA
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 47: China Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: China 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 50: China Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: China 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• EUROPE
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Anxiety Disorder Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• FRANCE
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 62: France Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: France 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 65: France Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: France 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• GERMANY
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 80: UK Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 83: UK Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Spain 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Russia 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Anxiety Disorder Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Australia 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Australia 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• INDIA
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 119: India Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: India 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 122: India Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: India 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: South Korea 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: South Korea 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Anxiety Disorder Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Argentina 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Argentina 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Brazil 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Brazil 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Mexico 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Mexico 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Rest of Latin America 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Rest of Latin America 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Anxiety Disorder Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Anxiety Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: Iran 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Iran 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Israel 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Israel 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Saudi Arabia 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Saudi Arabia 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: UAE 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: UAE 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Rest of Middle East 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Rest of Middle East 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• AFRICA
  • Anxiety Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Anxiety Disorder Treatment by Therapeutic Type - Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Africa 16-Year Perspective for Anxiety Disorder Treatment by Therapeutic Type - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents and Atypical Antipsychotics for the Years 2014, 2024 & 2030
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Anxiety Disorder Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Africa 16-Year Perspective for Anxiety Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030

IV. COMPETITION